IBDEI0BX ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5651,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5651,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,5651,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,5651,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,5652,0)
 ;;=446.6^^41^488^122
 ;;^UTILITY(U,$J,358.3,5652,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5652,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,5652,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,5652,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,5653,0)
 ;;=286.4^^41^488^125
 ;;^UTILITY(U,$J,358.3,5653,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5653,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,5653,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,5653,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,5654,0)
 ;;=204.00^^41^488^1
 ;;^UTILITY(U,$J,358.3,5654,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5654,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,5654,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,5654,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,5655,0)
 ;;=204.01^^41^488^3
 ;;^UTILITY(U,$J,358.3,5655,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5655,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,5655,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,5655,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,5656,0)
 ;;=204.10^^41^488^16
 ;;^UTILITY(U,$J,358.3,5656,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5656,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,5656,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,5656,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,5657,0)
 ;;=204.11^^41^488^18
 ;;^UTILITY(U,$J,358.3,5657,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5657,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,5657,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,5657,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,5658,0)
 ;;=201.90^^41^488^83
 ;;^UTILITY(U,$J,358.3,5658,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5658,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,5658,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,5658,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,5659,0)
 ;;=785.6^^41^488^89
 ;;^UTILITY(U,$J,358.3,5659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5659,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,5659,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,5659,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,5660,0)
 ;;=200.20^^41^488^90
 ;;^UTILITY(U,$J,358.3,5660,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5660,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,5660,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,5660,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,5661,0)
 ;;=202.00^^41^488^92
 ;;^UTILITY(U,$J,358.3,5661,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5661,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,5661,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,5661,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,5662,0)
 ;;=200.10^^41^488^91
 ;;^UTILITY(U,$J,358.3,5662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5662,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,5662,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,5662,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,5663,0)
 ;;=273.3^^41^488^93
 ;;^UTILITY(U,$J,358.3,5663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5663,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,5663,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,5663,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,5664,0)
 ;;=203.00^^41^488^103
 ;;^UTILITY(U,$J,358.3,5664,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5664,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,5664,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,5664,2)
 ;;=^267514
